The biotechnology sector witnesses another strategic maneuver as private equity firms GHO Capital Partners and Ampersand Capital Partners have agreed to acquire Avid Bioservices for $1.1 billion. Avid, an influential contract development and manufacturing organization (CDMO), specializes in
Rallybio, a small biotech firm, is on a mission to develop treatments for rare diseases, with a particular focus on fetal and neonatal alloimmune thrombocytopenia (FNAIT). This rare but potentially fatal disease results from platelet incompatibility between pregnant mothers and their unborn
In today's rapidly evolving field of biomanufacturing, traditional methods often fall short of the rigorous demands for real-time data and consistent product quality. Laser Force Cytology (LFC) has emerged as an innovative, label-free technology that offers a transformative approach to
Innovent Biologics Inc. (1801.HK), a significant player in the Chinese biopharmaceutical sector, recently faced harsh backlash from investors due to a misstep in its strategy. The company aimed to strengthen its executives' dedication to its international unit, Fortvita, by selling a stake to
In recent developments, Celltrion USA has significantly expanded the availability of its subcutaneous treatment for Crohn's disease and ulcerative colitis, Zymfentra, now accessible to 26 million patients across the United States. This milestone achievement is a result of the company’s s
ApiJect Systems Corp., a public-benefit medical technology company, has recently secured an initial grant of $425,000 from the Bill & Melinda Gates Foundation. This significant funding aims to support the design and development of low-cost Prefilled ApiJect Injectors to make single-use